Riluzole oral film formulation for amyotrophic lateral sclerosis

Riluzole oral film formulation is in clinical development for the treatment of patients with amyotrophic lateral sclerosis (ALS), a form of motor neurone disease (MND). ALS is a progressive disease where the nerve cells responsible for sending instructions to the muscles gradually deteriorate, leading to weakness, muscle wasting and paralysis. ALS is a debilitating and life-threatening disease. The gradual loss of neurons leads to a paralysing effect on muscles used for breathing, which usually leads to death from respiratory failure. Many patients with ALS have swallowing difficulties which can make taking standard care tablets difficult.